Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03486301
Recruitment Status : Recruiting
First Posted : April 3, 2018
Last Update Posted : September 5, 2021
Sponsor:
Collaborator:
Seven and Eight Biopharmaceuticals Inc
Information provided by (Responsible Party):
Birdie Biopharmaceuticals HK Limited

Tracking Information
First Submitted Date  ICMJE February 28, 2018
First Posted Date  ICMJE April 3, 2018
Last Update Posted Date September 5, 2021
Actual Study Start Date  ICMJE February 15, 2018
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 9, 2019)
Safety and Tolerability: incidence of adverse events and any dose limiting toxicity [ Time Frame: Up to 30 months ]
Safety and tolerability of BDB001 as a single agent and in combination with pembrolizumab as measured by the incidence of adverse events and any dose limiting toxicity
Original Primary Outcome Measures  ICMJE
 (submitted: March 27, 2018)
Safety and tolerability of BDB001 as a single agent and in combination with pembrolizumab as measured by the incidence of adverse events and any dose limiting toxicity [ Time Frame: Up to 30 months ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 20, 2019)
  • Determine Maximum Tolerated Dose [ Time Frame: From first dose to 21 days after first dose for each patient (cycle 1) ]
    Determination of the maximum tolerated dose by assessing the frequency of BDB001-related and BDB001 and pembrolizumab-related adverse events using CTCAE version 4.03 to categorize adverse event severity
  • Radiographic Determination of Tumor Response after BDB001 Dosing [ Time Frame: Every 63 days (3 cycles) up to 30 months after the first dose for each patient (each cycle is 21 days) ]
    Radiographic determination of tumor response in subjects dosed with BDB001 and BDB001 and pembrolizumab using irRECIST
Original Secondary Outcome Measures  ICMJE
 (submitted: March 27, 2018)
  • Determination of the maximum tolerated dose by assessing the frequency of BDB001-related and BDB001 and pembrolizumab-related adverse events using CTCAE version 4.03 to categorize adverse event severity [ Time Frame: From first dose to 21 days after first dose for each patient (cycle 1) ]
  • Calculation of the Area Under the Curve (AUC) [ Time Frame: Days 1, 8, and 9 of Cycle 1; then Day 1 of each successive cycle (each cycle is 28 days) ]
  • Calculation of the peak concentration (Cmax) [ Time Frame: Days 1, 8, and 9 of Cycle 1; then Day 1 of each successive cycle (each cycle is 28 days) ]
  • Calculation of the time of maximum concentration (Tmax) [ Time Frame: Days 1, 8, and 9 of Cycle 1; then Day 1 of each successive cycle (each cycle is 28 days) ]
  • Calculation of the half-life (T1/2) [ Time Frame: Days 1, 8, and 9 of Cycle 1; then Day 1 of each successive cycle (each cycle is 28 days) ]
  • Quantitative measurement of cytokines after dosing with BDB001 and BDB001 and pembrolizumab by collection of plasma samples [ Time Frame: Days 1, 8, and 9 of Cycle 1 (each cycle is 28 days) ]
  • Quantitative measurement of RNA species after dosing with BDB001 and BDB001 and pembrolizumab by collection of plasma samples [ Time Frame: Days 1, 8, and 9 of Cycle 1 (each cycle is 28 days) ]
  • Radiographic determination of tumor response in subjects dosed with BDB001 and BDB001 and pembrolizumab using irRECIST [ Time Frame: Every 63 days (3 cycles) up to 30 months after the first dose for each patient (each cycle is 28 days) ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
Official Title  ICMJE Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Brief Summary Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Detailed Description

This clinical trial is a study of an experimental drug called BDB001. BDB001 is a Toll-like receptor (TLR) agonist that activates the immune system.

The primary objectives of this study are to evaluate the safety and tolerability of BDB001 as a single agent and in combination with pembrolizumab and to determine the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) when given in combination with pembrolizumab in subjects with advanced solid tumors.

This is a multi-center, open-label, dose escalation/dose expansion Phase 1 study of BDB001 as a single agent and in combination with pembrolizumab in subjects with histologically-confirmed, incurable, unresectable or metastatic solid tumors that have relapsed or are refractory to standard therapies or for whom there is no approved therapy.

The study will be conducted in two separate but independent dose escalation arms: a single agent arm (BDB001 alone) and a combination arm (BDB001 in combination with pembrolizumab).

Participants will be allowed to continue treatment beyond study termination until occurrence of significant treatment-related toxicity, progressive disease or discontinuation criteria are met.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Tumor, Solid
Intervention  ICMJE
  • Drug: BDB001
    BDB001 is an immunotherapy agent.
  • Drug: Pembrolizumab
    Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Study Arms  ICMJE
  • Experimental: Single Agent BDB001

    A single subject will be enrolled at each dose level in the single agent arm until any ≥ Grade 2 treatment-emergent adverse event (TEAE) is observed in the first cycle.

    Then dosage escalation will follow a traditional 3+3 dose escalation design.

    Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB001 is reached.

    Intervention: Drug: BDB001
  • Experimental: BDB001 in Combination with Pembrolizumab

    In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.

    When the MTD or RP2D of single agent BDB001 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, twenty additional subjects will be enrolled in the expansion phase of the study.

    Interventions:
    • Drug: BDB001
    • Drug: Pembrolizumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 27, 2018)
50
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2022
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Be 18 years of age on day of signing informed consent
  2. Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors who have disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. Note: there is no limit to the number of prior treatment regimens
  3. A male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period
  4. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP)
    2. A WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment • A highly effective method of contraception is defined as one that results in a low failure rate (i.e., less than 1% per year, when used consistently and correctly)
  5. Evidence of progressive disease (PD) within 3 months of signing the informed consent form
  6. Have measurable disease per irRECIST as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  7. Eastern Cooperative Oncology Group (ECOG) score of 0 - 2
  8. Minimum life expectancy of 3 months
  9. Have adequate organ function as defined by the protocol. Specimens must be collected within 10 days prior to the start of study treatment.

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

  1. A woman of child bearing potential who has a positive urine pregnancy test (e.g. within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  2. Prior exposure to TLR 7 agonists (e.g., GS-9620, imiquimod, TMX 101, resiquimod, MEDI9197, 825A) and TLR 9 agonists (e.g., SD-101, IMO2125, MGN1703, GNKG168, DUK-CPG-001 and CMP-001) for treatment of the solid tumor the patient is currently being evaluated for treatment with BDB001.
  3. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher irAE
  4. Received previous therapy for malignancy within 21 days prior to administration of study drug, including any investigational agents (other than BDB001), chemotherapy, immunotherapy, biological or hormonal therapy (6 weeks for nitrosoureas or mitomycin C)
  5. Major surgery within 4 weeks of first dose of study drug
  6. Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease
  7. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed
  8. Currently receiving medications known to be strong inhibitors of CYP1A and CYP3A and strong/moderate inducers of CYP1A and CYP3A
  9. Receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
  10. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 21 days prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent
  11. History within last 6 months of New York Heart Association Class III or IV heart failure, acute myocardial infarction, angina pectoris, uncontrolled arrhythmia, acute coronary syndromes, stent placement, uncontrolled hypertension
  12. QTc interval value > 470 msec (using Fridericia's Correction)
  13. Left ventricular ejection fraction (LVEF) < 50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
  14. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment (Kim 2017).
  15. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
  16. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority
  17. Known active hepatitis A, B or C. Subjects who are HBsAg+ and have DNA load < 2000 IU/mL (104 copies/mL) are eligible to participate in the study provided they meet the ALT and bilirubin inclusion criteria.
  18. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  19. Has an active infection requiring systemic therapy
  20. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  21. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  22. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.
  23. Has had an allogenic tissue/solid organ transplant
  24. Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
  25. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  26. History of interstitial lung disease
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Robert Andtbacka, MD,CM, 18483000086 randtbacka@7and8biopharma.com
Contact: Melissa Harney 18483000086 mharney@7and8biopharma.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03486301
Other Study ID Numbers  ICMJE BDB001-101
KN-914 ( Other Identifier: Merck Sharp & Dohme Corp )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Birdie Biopharmaceuticals HK Limited
Study Sponsor  ICMJE Birdie Biopharmaceuticals HK Limited
Collaborators  ICMJE Seven and Eight Biopharmaceuticals Inc
Investigators  ICMJE
Study Chair: Robert Andtbacka, MD, CM, Seven and Eight Biopharmaceuticals Inc
PRS Account Birdie Biopharmaceuticals HK Limited
Verification Date September 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP